Eli Lilly PE Ratio 2006-2018 | LLY

Current and historical PE ratio for Eli Lilly (LLY) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Eli Lilly (LLY) as of March 31, 2018 is 19.33.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.940B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.858B 16.72
Pfizer (PFE) United States $223.411B 13.75
Novartis AG (NVS) Switzerland $182.569B 15.82
Merck (MRK) United States $169.563B 15.15
AbbVie (ABBV) United States $153.340B 15.64
Novo Nordisk (NVO) Denmark $121.883B 20.19
Sanofi (SNY) France $105.164B 13.31
GlaxoSmithKline (GSK) United Kingdom $103.492B 14.15
AstraZeneca (AZN) United Kingdom $94.122B 9.86
Bristol-Myers Squibb (BMY) United States $92.940B 18.28